EW Stock Analysis: Edwards Lifesciences | NYSE
Medical Devices | NYSE, USA | Market Cap: 58.113m USD | 12M Return: 24.4% | US28176E1082 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 407M
EPS Trend: 72.5%
Qual. Beats: 3
Rev. Trend: 97.4%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 11.8 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Edwards Lifesciences Corporation is a U.S.-based medical device company specializing in products and technologies for treating advanced cardiovascular diseases, with operations spanning the United States, Europe, Japan, and other international markets. Founded in 1958 and headquartered in Irvine, California, the company operates within the Health Care Equipment sub-industry and is classified as a large-cap stock on the NYSE under the ticker EW.
The companys portfolio is organized around three main structural heart franchises: transcatheter heart valve replacement products under the Edwards SAPIEN family of valves; transcatheter repair and replacement products for mitral and tricuspid valve diseases marketed under the PASCAL and EVOQUE brands; and surgical structural heart solutions, which include the INSPIRIS, KONECT RESILIA, and MITRIS RESILIA valve platforms. These offerings are part of the broader structural heart device market, a specialized medical device segment focused on valves and other cardiac anatomy, where transcatheter approaches have become an increasingly important minimally invasive alternative to traditional open-heart surgery.
Edwards Lifesciences distributes its products through a combination of a direct sales force and independent distributors. A notable feature of its surgical portfolio is the proprietary RESILIA tissue technology, a treated bovine pericardial tissue platform designed to resist calcification, which underpins several of its valve products.
- TAVR procedure volume growth in US and Europe
- Mitral and tricuspid repair products PASCAL EVOQUE gain market share
- Surgical heart segment faces younger patient competition from TAVR
| Net Income: 1.02b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 0.98 > 1.0 |
| NWC/Revenue: 84.96% < 20% (prev 81.09%; Δ 3.87% < -1%) |
| CFO/TA 0.12 > 3% & CFO 1.72b > Net Income 1.02b |
| Net Debt (-3.83b) to EBITDA (1.76b): -2.18 < 3 |
| Current Ratio: 4.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (577.6m) vs 12m ago -1.38% < -2% |
| Gross Margin: 78.13% > 18% (prev 78.22%; Δ -0.09% > 0.5%) |
| Asset Turnover: 48.69% > 50% (prev 44.33%; Δ 4.36% > 0%) |
| Interest Coverage Ratio: 77.75 > 6 (EBIT TTM 1.59b / Interest Expense TTM 20.4m) |
| A: 0.40 (Total Current Assets 7.25b - Total Current Liabilities 1.58b) / Total Assets 14.1b |
| B: 1.07 (Retained Earnings 15.2b / Total Assets 14.1b) |
| C: 0.12 (EBIT TTM 1.59b / Avg Total Assets 13.7b) |
| D: 3.41 (Book Value of Equity 10.9b / Total Liabilities 3.18b) |
| Altman-Z'' = 10.49 = AAA |
| DSRI: 0.93 (Receivables 937.8m/892.8m, Revenue 6.67b/5.88b) |
| GMI: 1.00 (GM 78.22% / 78.13%) |
| AQI: 0.91 (AQ_t 0.35 / AQ_t-1 0.38) |
| SGI: 1.13 (Revenue 6.67b / 5.88b) |
| TATA: -0.05 (NI 1.02b - CFO 1.72b) / TA 14.1b) |
| Beneish M = -3.05 (Cap -4..+1) = AA |
As of November 16, 2026, the stock is trading at USD 107.15 with a total of 3,821,974 shares traded. Over the past week, the price has changed by +4.91%, over one month by +25.66%, over three months by +15.76% and over the past year by +24.43%.
Current recommended Stop Loss: 103.60 (which is 3.3% or 1.2 ATR below the current price).
Edwards Lifesciences has received a consensus analysts rating of 4.37. Therefore, it is recommended to buy EW.
- StrongBuy: 18
- Buy: 5
- Hold: 7
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 102.5 | -4.3% |
P/E Trailing = 60.0119
P/E Forward = 29.3255
P/S = 8.9142
P/B = 5.3943
P/EG = 2.0789
Revenue TTM = 6.67b USD
EBIT TTM = 1.59b USD
EBITDA TTM = 1.76b USD
Long Term Debt = 598.8m USD (from longTermDebt, last quarter)
Short Term Debt = 24.9m USD (from shortTermDebt, last quarter)
Debt = 810.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 105.7m
Net Debt = -3.83b USD (calculated: Debt 810.2m - CCE 4.64b)
Enterprise Value = 54.3b USD (58.1b + Debt 810.2m - CCE 4.64b)
Interest Coverage Ratio = 77.75 (Ebit TTM 1.59b / Interest Expense TTM 20.4m)
EV/FCF = 38.11x (Enterprise Value 54.3b / FCF TTM 1.42b)
FCF Yield = 2.62% (FCF TTM 1.42b / Enterprise Value 54.3b)
FCF Margin = 21.34% (FCF TTM 1.42b / Revenue TTM 6.67b)
Net Margin = 15.30% (Net Income TTM 1.02b / Revenue TTM 6.67b)
Gross Margin = 78.13% ((Revenue TTM 6.67b - Cost of Revenue TTM 1.46b) / Revenue TTM)
Gross Margin QoQ = 78.48% (prev 77.56%)
Tobins Q-Ratio = 3.84 (Enterprise Value 54.3b / Total Assets 14.1b)
Interest Expense / Debt = 2.52% (Interest Expense 20.4m / Debt 810.2m)
Taxrate = 31.05% (444.7m / 1.43b)
NOPAT = 1.09b (EBIT 1.59b * (1 - 31.05%))
Current Ratio = 4.60 (Total Current Assets 7.25b / Total Current Liabilities 1.58b)
Debt / Equity = 0.07 (Debt 810.2m / totalStockholderEquity, last quarter 10.9b)
Debt / EBITDA = -2.18 (Net Debt -3.83b / EBITDA 1.76b)
Debt / FCF = -2.69 (Net Debt -3.83b / FCF TTM 1.42b)
Total Stockholder Equity = 10.5b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.45% (Net Income 1.02b / Total Assets 14.1b)
RoE = 9.69% (Net Income TTM 1.02b / Total Stockholder Equity 10.5b)
RoCE = 14.25% (EBIT 1.59b / Capital Employed (Equity 10.5b + L.T.Debt 598.8m))
RoIC = 8.92% (NOPAT 1.09b / Invested Capital 12.3b)
WACC = 6.70% (E(58.1b)/V(58.9b) * Re(6.77%) + D(810.2m)/V(58.9b) * Rd(2.52%) * (1-Tc(0.31)))
Discount Rate = 6.77% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.56 | Cagr: -1.99%
[DCF] Terminal Value 77.97% ; FCFF base≈1.34b ; Y1≈1.53b ; Y5≈2.26b
[DCF] Fair Price = 65.53 (EV 33.9b - Net Debt -3.83b = Equity 37.8b / Shares 576.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 72.51 | EPS CAGR: 3.74% | SUE: 1.87 | # QB: 3
Revenue Correlation: 97.44 | Revenue CAGR: 10.22% | SUE: 0.21 | # QB: 0
EPS current Quarter (2027-03-31): EPS=0.84 | Chg30d=+0.32% | Revisions=-18% | Analysts=15
EPS current Year (2026-12-31): EPS=3.00 | Chg30d=+0.01% | Revisions=+25% | GrowthEPS=+17.2% | GrowthRev=+11.4%
EPS next Year (2027-12-31): EPS=3.38 | Chg30d=+0.15% | Revisions=+0% | GrowthEPS=+12.8% | GrowthRev=+9.9%
[Analyst] Revisions Ratio: -7% (up=5, down=6)